OMEROS CORP Senior Notes, Noncurrent
OMEROS CORP (OMER) had Senior Notes, Noncurrent of $42.03 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Notes and Loans, Noncurrent
us-gaap:SeniorLongTermNotes · last filed 2026-08-12
- 2026-06-30: Senior Notes, Noncurrent $42.03M.
- 2026-03-31: Senior Notes, Noncurrent $52.81M.
- 2025-12-31: Senior Notes, Noncurrent $51.36M.
- 2025-09-30: Senior Notes, Noncurrent $72.08M.
| Period end | Senior Notes, Noncurrent |
|---|---|
| 2026-06-30 | $42.03M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $52.81M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $51.36M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $72.08M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $63.47M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $70.40M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $97.18M 10-K · filed 2026-03-31 |
| 2024-09-30 | $97.03M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $96.89M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $213.46M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $213.16M 10-K · filed 2025-03-31 |
| 2023-09-30 | $221.83M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $221.52M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $221.21M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $220.91M 10-K · filed 2024-04-01 |
| 2022-09-30 | $314.82M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $314.36M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $313.90M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $313.46M 10-K · filed 2023-03-13 |
| 2021-09-30 | $313.02M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $312.58M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $312.16M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $236.29M 10-K · filed 2022-03-01 |
| 2020-09-30 | $232.81M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $163.37M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $160.75M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $158.21M 10-K · filed 2021-03-01 |
| 2019-09-30 | $155.77M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $153.42M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $151.18M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $148.98M 10-K · filed 2020-03-02 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |